Global Prefrontal and Fronto-amygdala Dysconnectivity in Bipolar I Disorder with Psychosis History

Alan Anticevic¹,²,³,⁎, Margaret S. Brumbaugh⁴,⁎, Anderson M. Winkler¹,⁴, Lauren E. Lombardo⁴, Jennifer Barrett⁴, Phillip R. Corlett¹, Hedy Kober⁵,⁶, June Gruber⁵,¹, Grega Repovs⁶, Michael W. Cole⁷, John H. Krystal¹,²,³, Godfrey D. Pearlson¹,⁴,⁸, and David C. Glahn¹,⁴

¹Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT, 06511, USA
²NIAAA Center for the Translational Neuroscience of Alcoholism, New Haven, CT 06519
³Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT

© 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Financial Disclosures
Dr. John H. Krystal discloses the following: Consultant Note: ± The Individual Consultant Agreements listed below are less than $10,000 per year
Aisling Capital, LLC; AstraZeneca Pharmaceuticals; Biocortech; Brintnall & Nicolin, Inc.; Easton Associates; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Lundbeck Research USA; Medivation, Inc.; Merz Pharmaceuticals; MK Medical Communications; F. Hoffmann-La Roche Ltd; SK Holdings Co., Ltd; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Teva Pharmaceutical Industries, Ltd.

Scientific Advisory Board
Abbott Laboratories; Bristol-Myers Squibb; Eisai, Inc.; Eli Lilly and Co.; Forest Laboratories, Inc.; Lohocla; Research Corporation; Mnemosyne Pharmaceuticals, Inc.; Naurex, Inc.; Pfizer Pharmaceuticals; Shire Pharmaceuticals

Exercisable Warrant Options
Tetragenex Pharmaceuticals (value less than $150)

Board of Directors:
Coalition for Translational Research in Alcohol and Substance Use Disorders

President Elect:
American College of Neuropsychopharmacology

Research Support to Department of Veterans Affairs
Janssen Research Foundation (Provided drug and some study support to the Department of Veterans Affairs)

Editorial Board
Income Greater than $10,000
Editor - Biological Psychiatry

Employment:
Yale University School of Medicine
VA CT Healthcare System

Patents and Inventions
2) I am a co-inventor with Dr. Gerard Sanacora on a filed patent application by Yale University related to targeting the glutamatergic system for the treatment of neuropsychiatric disorders (PCTWO06108055A1).
3) Intranasal Administration of Ketamine to Treat Depression (pending)
Dr. Corlett reports no biomedical financial interests or potential conflicts of interest relevant to this work, but for unrelated activities, consults for Pfizer and Johnson & Johnson and has received research support from Pfizer and AstraZeneca. All other authors report no biomedical financial interests or potential conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Abstract

Background—Pathophysiological models of bipolar disorder postulate that mood dysregulation arises from fronto-limbic dysfunction, marked by reduced prefrontal cortex (PFC) inhibitory control. This may occur both due to disruptions within PFC networks and abnormal inhibition over subcortical structures involved in emotional processing. However, no study has examined global PFC dysconnectivity in bipolar disorder and tested if regions with within-PFC dysconnectivity also exhibit fronto-limbic connectivity deficits. Further, no study has investigated whether such connectivity disruptions differ for bipolar patients with psychosis history, who may exhibit a more severe clinical course.

Methods—We collected resting-state fMRI at 3T in 68 remitted bipolar I patients (34 with psychosis history) and 51 demographically-matched healthy participants. We employed a recently developed Global Brain Connectivity method, restricted to PFC (rGBC). We also independently tested connectivity between anatomically-defined amygdala and PFC.

Results—Bipolar patients exhibited reduced medial PFC (mPFC) rGBC, increased amygdala-MPFC connectivity, and reduced connectivity between amygdala and dorso-lateral PFC. All effects were driven by psychosis history. Moreover, the magnitude of observed effects was significantly associated with lifetime psychotic symptom severity.

Conclusions—This convergence between rGBC, seed-based amygdala findings and symptom severity analyses highlights that mPFC, a core emotion regulation region, exhibits both within-PFC dysconnectivity and connectivity abnormalities with limbic structures in bipolar illness. Furthermore, lateral PFC dysconnectivity in patients with psychosis history converges with published work in schizophrenia, indicating possible shared risk factors. Observed dysconnectivity in remitted patients suggests a bipolar trait characteristic and may constitute a risk factor for phasic features of the disorder.

Keywords
bipolar disorder; prefrontal cortex; amygdala; connectivity; resting-state; psychosis

Introduction

Bipolar disorder is characterized by prominent mood dysregulation(1). Pathophysiological models of bipolar illness suggest this dysregulation may arise from both dysfunction in prefrontal cortical (PFC) networks linked to cognitive control of emotion, and disruptions in prefrontal control over subcortical regions involved in affective processing like the amygdaloid complex(2). Functional magnetic resonance imaging (fMRI) findings support this model by demonstrating abnormalities across subcortical/limbic and cortical structures, notably the amygdala and medial PFC (mPFC)(3). These regions show mood-state-dependent activity alterations in bipolar disorder and have been linked to emotion generation and appraisal(4–7). Moreover, individuals with bipolar disorder show aberrant prefrontal activation across cognitive challenges(6, 8), suggesting possible disturbances in prefrontal...
function. However, PFC is large and heterogeneous with widespread connectivity and it is unclear which specific prefrontal circuits may be compromised in this disorder. While evidence supports that localized structure and function of mPFC is disrupted in bipolar disorder(8), there is relatively little information about the relationships between prefrontal cortical regions in bipolar illness. Complex neuropsychiatric disease like bipolar disorder may result from disrupted neural computations across networks of regions(9). Indeed, severe mood disorders are associated with abnormal structural plasticity and cellular resilience(10–12), which may give rise to impairments in distributed neural networks(9). Therefore, it is critical to identify prefrontal circuitry exhibiting distributed PFC functional abnormalities, which may relate to deficits in both PFC function and control over limbic structures. Yet, prefrontal dysconnectivity has not been systematically investigated in this illness.

A growing body of evidence shows that distributed neural circuits exhibit spontaneous activity at rest(13). These slow-frequency fluctuations are temporally correlated within spatially-distinct but functionally-related networks(14), establishing an intrinsic functional network architecture (15) across primate species(16). These networks show high concordance with other measures of structural and functional connectivity in healthy populations(17) and provide an opportunity to characterize distributed circuit abnormalities in neuropsychiatric illnesses(18). Prior research using resting-state techniques demonstrates that individuals with bipolar disorder show reduced connectivity within the “default mode network”(19), the pregenual anterior cingulate, thalamus and amygdala(20), as well as in the ventral prefrontal-amygdala pathways(21). Although these findings constitute important advances in our understanding of bipolar disorder, no study to date has investigated global prefrontal dysconnectivity patterns (i.e. across all prefrontal gray matter voxels). Such a global, data-driven approach is vital as it allows comprehensive examination of prefrontal connectivity abnormalities. This in turn offers the potential to identify specific prefrontal nodes compromised in bipolar illness, which may also relate to regulation of limbic circuits.

Although identifying global prefrontal network disruption in bipolar illness is critical, such findings do not imply fronto-limbic dysconnectivity. To establish fronto-limbic dysconnectivity, both prefrontal and limbic connectivity must be assessed in the same subjects. It is well recognized that amygdala shares dense connectivity with prefrontal cortex, most notably caudal orbitofrontal cortex, mPFC and anterior cingulate gyrus(22–25) – all regions implicated in regulation of emotion (among other functions). The critical point of such analyses is to independently test if the same (or similar) regions identified via global connectivity may also exhibit connectivity disturbances with the amygdala. That is, examining deficits in limbic connectivity with broad PFC circuits is key to fully characterize deficits in fronto-limbic dysregulation in bipolar disorder.

While we discussed bipolar disorder as a diagnostic category, bipolar illness is highly heterogeneous in terms of onset, symptom severity, co-morbidity, clinical course, and outcome. Such diversity implies that distinct, yet partially overlapping neurobiological mechanisms may be involved in patients with differing clinical presentations. Capitalizing on a dimensional approach(26) we can identify subpopulations of patients with common symptoms or illness-course who may exhibit shared neural dysfunction. One potential axis upon which to subdivide bipolar disorder is the presence or absence of psychotic symptoms. Psychotic symptoms are present in 50–70% of individuals with bipolar disorder(27, 28) and psychosis aggregates within families of bipolar patients(29). Lifetime history of psychosis may represent a more severe form of the illness associated with poorer prognosis((30, 31); but see(32)), cognitive performance(33), brain structure(34) and function(35). Recent reports of global prefrontal dysconnectivity in schizophrenia(36) raises the intriguing hypothesis that history of psychosis in bipolar disorder may be associated with more severe
patterns of prefrontal dysconnectivity. However, prefrontal dysconnectivity has yet to be examined in psychotic bipolar disorder.

Our goal was to investigate prefrontal-limbic dysconnectivity in bipolar disorder. We tested three hypotheses: First, we examined whether there are global PFC connectivity abnormalities in this illness by applying a recently developed global brain connectivity method(37–39), which may particularly manifest in mPFC. Second, we compared patients with a history of psychosis versus patients without psychosis to determine if psychotic patients exhibit more severe PFC dysconnectivity, similar to findings in schizophrenia(36). Third, we examined functional connectivity between the amygdala and PFC using independent anatomically-delineated seeds. We specifically tested whether regions showing global prefrontal disturbances exhibit convergence with amygdala dysconnectivity.

**Methods**

**Participants**

Participants provided informed consent approved by the IRB at Hartford Hospital and Yale University. Sixty-eight remitted patients with bipolar I disorder and 51 demographically-matched healthy individuals participated in the study (Table 1). Patients were identified through outpatient clinics and community mental health facilities in the Hartford area. Inclusion criteria for patients were: i) bipolar I disorder diagnosis as determined by the Structured Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)(40), administered by experienced MA or PhD-level research clinicians; ii) no history of major medical or neurological conditions (e.g. epilepsy, migraine, head trauma with loss of consciousness); and iii) IQ>80 assessed by Wechsler Abbreviated Intelligence Scale(41). To increase ecological validity of the patient sample, co-morbid Axis I anxiety disorders and/or history of substance abuse (fully remitted >6 months prior to the study) were allowed. Healthy participants were recruited through media advertisements and flyers posted in the Medical Center area. Inclusion criteria for healthy participants were: i) no current or lifetime Axis I psychiatric disorder as assessed by SCID-NP; ii) no history of medical or neurological conditions; and iii) no history of psychotic or mood disorders in first-degree relatives (reported by detailed family history). While groups were matched for age, ethnicity, and sex, healthy participants’ education attainment was greater than that of patients with bipolar disorder (p=.01)(42). Education differences are impacted by the illness course(43) and thus were not included as a covariate; alcohol, drug use, anxiety, age, illness duration, gender and medication type did not alter reported effects.

**Current Symptoms & Medication**

Severity of current mood symptoms was determined with the 21-item Hamilton Depression scale (HAM-D)(44), the Young Mania Rating Scale (YMRS)(45), and the expanded version of the Brief Psychiatric Rating Scale (BPRS)(46). Only remitted patients were included in the current experiment (>1 week), defined using standardized cutoffs on the HAM-D (less than or equal to 7) and YMRS (less than or equal to 7) (Table 1). 53% of bipolar patients were receiving mood stabilizers, 43% were taking antidepressants, 34% were taking atypical antipsychotics, 35% were taking anxiolytics, 16% were on lithium, and 16% were unmedicated at the time of assessment (note: some patients were on multiple medications). As noted, reported effects were not altered when we co-varied for medication. For details on psychosis history evaluation for bipolar patients with psychosis (BPP) vs. those without psychosis (BWP) see Supplement.
**GBC Analysis**

Complete fMRI acquisition and preprocessing details are presented in the Supplement. The *global brain connectivity* (GBC) approach (36, 38) was applied using in-house Matlab tools. GBC estimates the connectivity between each individual voxel and every other voxel in the brain. In contrast, restricted GBC estimates connectivity at every voxel with every other voxel in a restricted space (referred to hereafter as *restricted global brain connectivity* - rGBC). Here we conducted rGBC analysis restricted to voxels within subject-specific FreeSurfer-based (47) prefrontal gray matter masks (see Supplement for FreeSurfer segmentations that comprised the mask). To account for between-subject differences in anatomy, before the analysis, BOLD signal within the subject-specific cortical mask was spatially smoothed with a 6mm full-width-at-half-maximum (FWHM) Gaussian kernel and dilated by two voxels (6mm) to account for individual differences in anatomy. Following our prior work (36), the rGBC analysis involved, for each PFC voxel, computing a correlation with every other PFC voxel, transforming the correlations to Fisher z-values, and computing the mean. This yielded a map for each subject where each voxel value represents the mean connectivity of that voxel with the rest of PFC.

**Amygdala Seed-based Functional Connectivity (fcMRI) Analysis**

The seed-based amygdala fcMRI closely followed our prior work (48). As with rGBC, we employed in-house Matlab tools (49, 50) to examine the relationship between amygdala and all PFC voxels. To this end, we computed a seed-based amygdala correlation map by extracting average time-series across all voxels in each subject’s bilateral amygdala (anatomically defined through FreeSurfer-based segmentation (47, 51)), which was then correlated with each PFC voxel. Next, as with rGBC, we computed a Fisher r-to-Z transform, which yielded a map for each subject where each PFC voxel value represents connectivity with the amygdala.

**2nd-Level Group Analysis**

Before computing group-level statistics, individual amygdala fcMRI and rGBC correlation maps were converted to Fisher-Z maps. To examine hypothesized between-group differences, these maps were entered into 1-way ANOVAs with three across-group levels (controls, BPP, BPW). Both analyses were corrected within the anatomically-defined PFC mask (95% overlap across all subjects). Type I error correction was based on peak and cluster extent (52) ascertained via AFNI’s AlphaSim with exact smoothness estimates computed from the general linear model residuals (p<.001, k=14 voxels for rGBC and k=13 for amygdala fcMRI). Results were visualized using Caret 5.5 software (http://brainvis.wustl.edu/wiki/index.php/Caret).

**Results**

**Global Prefrontal Connectivity in Bipolar Disorder**

To test hypothesized between-group difference in rGBC we computed a 1-way ANOVA. Results revealed a significant *Group* effect centered on mPFC (x=3, y=32, z=1) (Figure 1A). This effect was largely driven by reduced connectivity for bipolar patients with psychosis history. Notably, healthy participants did not exhibit any regions of reduced prefrontal connectivity relative to the bipolar group, despite virtually identical SNR. To confirm that a history of psychosis is associated with more severe prefrontal dysconnectivity, we computed two follow-up independent-sample t-tests. Patients with psychosis history showed lower mPFC rGBC compared to healthy controls [t(83)=4.31, p<.001], and when compared to bipolar patients without psychosis history [t(66)=3.51, p<.001] (Figure 1B). Pair-wise comparisons were also significant when corrected within the PFC mask as a whole,
illustrating the robustness of this effect. We also present a direct comparison of controls vs. the entire sample of bipolar patients for qualitative inspection in the Supplement (Figure S1).

Amygdala-Prefrontal Connectivity in Bipolar Disorder

To circumvent region selection bias and to ensure complete independence from observed rGBC effects (see Supplement for more detailed independence considerations), we computed a separate anatomically defined amygdala seed-based analysis with PFC, and examined the main effect of Group in a 1-way ANOVA. If we were to seed from the mPFC and indeed identify differences centered around the amygdala one could raise the issue of circularity (as those functional voxels were defined using the present analysis)(53). Results revealed two foci showing significant between-group effects (Figure 2A–B): centered on mPFC (x=1, y=41, z=−3) and right dorso-lateral PFC (DLPFC) (x=34, y=43, z=30). Again, amygdala-mPFC findings were predominantly driven by bipolar patients with psychosis history. However, in contrast to rGBC effects, patients with psychosis history showed focal increased connectivity between the amygdala and mPFC relative to healthy controls \[t(83)=4.5, p<.001\] and relative to bipolar patients without psychosis \[t(66)=2.76, p<.007\] (Figure 2A). Conversely, for the amygdala-DLPFC region, bipolar patients with psychosis history evidenced more negative connectivity relative to controls \[t(83)=4.62, p<.001\] and patients without psychosis history \[t(66)=4.11, p<.001\] (Figure 2B). To allow complete interpretation of amygdala findings we present threshold-free patterns for controls and bipolar patients in the Supplement (Figure S2).

Testing for Convergence of rGBC and Amygdala Connectivity Effects

Given our questions regarding both frontal and limbic dysconnectivity, we tested whether the voxels identified through a given analysis showed convergent effects with the other analysis. That is, given complete independence of identified regions, we tested rGBC effects in the mPFC voxels identified via amygdala connectivity and vice versa (i.e. amygdala connectivity effects in the mPFC voxels identified via rGBC). The purpose of the convergence analysis was to test whether identified voxels across the two approaches represent functionally distinct regions. Both effects converged: i) the rGBC effect remained significant and consistent in the mPFC region identified via amygdala connectivity \[F(2,116)=6.8, p<.002\]; ii) the amygdala-mPFC effect remained significant and consistent in the mPFC region identified via rGBC analysis \[F(2,116)=3, p=.05\]. Together, these findings further argue that functionally similar effects were present for both analyses across independently identified mPFC voxels.

Lifetime Psychotic Symptom Severity

To additionally examine the association between observed dysconnectivity and psychosis, we correlated measures of lifetime psychotic symptoms derived using the Lifetime Dimensions of Psychosis Scale (LDPS) (see Supplement) with regions that revealed between-group effects. We computed a Spearman’s correlation coefficient due to non-normally distributed symptom scores (i.e. some patients had no psychotic symptoms). We focused on positive symptoms because few patients reported lifetime negative/disorganization symptoms. There was an inverse relationship between severity of lifetime positive symptoms and mPFC rGBC \[\rho=-.22, p=.07\] indicating that patients with more severe lifetime positive psychotic symptoms (e.g. hallucinations and delusions) exhibit even lower mPFC rGBC (Figure 3A). In contrast, elevated amygdala-mPFC coupling was associated with increased lifetime psychotic symptom severity \[\rho=.31, p<.015\] (Figure 3B), whereas lower amygdala-DLPFC coupling was associated with more severe symptoms \[\rho=-.44, p<.001\] (Figure 3C). We carried out further sub-group analysis with only those
patients exhibiting psychotic symptoms (N=50, see Supplement), which revealed a consistent, but attenuated pattern.

Discussion

We investigated PFC connectivity in bipolar I disorder and found, consistent with predictions: i) significant between-group differences in mPFC rGBC, particularly prominent for patients with psychosis history compared to those without and controls; ii) increased connectivity for amygdala-mPFC and lower connectivity for amygdala-DLPFC networks in bipolar patients relative to controls that was exaggerated in patients with psychosis history; and iii) that the magnitude of observed effects scaled with lifetime symptom severity. These findings provide evidence for distributed dysconnectivity between mPFC and other prefrontal regions and focal fronto-limbic dysconnectivity between mPFC and amygdala.

Global Prefrontal and Fronto-Limbic Connectivity

We hypothesized that bipolar patients would exhibit global prefrontal dysconnectivity in regions associated with affect regulation, such as mPFC, based on prior work indicating their critical role in regulating emotion(24). Consistent with predictions, we identified a focal mPFC region for which patients showed reduced connectivity relative to healthy controls. These regional findings are highly consistent with both meta-analytic and seed-based neuroimaging studies reporting focal differences in bipolar disorder(6, 54). However, this is the first investigation to directly document reduced functional integration between mPFC with the rest of prefrontal cortex in bipolar disorder. Present findings illustrate that widespread prefrontal functional disruptions with mPFC may underlie risk for affect deregulation, which constitutes the hallmark symptom of this illness (as patients were euthymic at the time of the scan and therefore observed differences cannot be attributed to present affect regulation deficits). Interestingly, this region showed reduced global prefrontal connectivity in patients with psychosis history relative to other groups (discussed below).

As noted, mPFC is involved in regulation of affect through dense and reciprocal connectivity with subcortical regions implicated in generation of affective states (e.g. amygdala)(22). Yet, the rGBC analysis does not guarantee that identified regions exhibit deficits in regulation of limbic circuits. That is, the rGBC analysis included prefrontal cortex, not subcortical limbic regions, leaving open the possibility that the mPFC region identified as showing lower prefrontal connectivity might independently show reduced subcortical limbic connectivity. Thus, we examined potential convergence between rGBC and seed-based amygdala-PFC connectivity. Our independent amygdala analysis revealed a region in close proximity to the rGBC effect (although not precisely overlapping) – indicating that similar cortical territories that exhibit reduced PFC integration may also be involved in reduced limbic regulation in bipolar illness. Moreover, when we tested for convergence of effects across analysis (given their statistical independence), we found highly similar results across both identified regions. Present findings further solidify – through two independent but convergent approaches – that mPFC plays a critical role in the pathophysiology of bipolar illness.

Previous resting-state studies in humans and tracing studies in primates have shown that a portion of the medial PFC exhibits positive connectivity with the amygdala(22, 24, 25, 55–58), which we observed in our prior work(48) and here (threshold-free amygdala maps shown in Supplement). In Figure 2A the identified mPFC region exhibits low connectivity with amygdala in controls, which is increased in patients. Therefore, what does it mean if connectivity exists in a patient population that is ‘low’ in healthy subjects? It has been well-established that functional connectivity is dynamic and state-dependent(59) whereby a low
resting-state value may change and become more positive during times when emotional regulation is warranted. Thus, the observed increased values in bipolar illness may reflect a ‘state’ that exists due to a heightened need for mood regulation (as proposed in the context of fear extinction.(60)). There is also the possibility that the connection ‘weight’ changes from frequent attempts to regulate mood. In other words, patients may be in a different state in day-to-day life frequently enough that resting amygdala-mPFC connectivity has altered (in a Hebbian sense)(59). We acknowledge that these hypotheses are speculative, yet they highlight scenarios where low coupling in the normative sample, but an increase in the clinical sample, may reflect a meaningful disturbance in amygdala-mPFC connectivity. Further work is needed to verify these possibilities. In addition, we opted for a PFC-wide amygdala seed-based analysis (as opposed to a restricted one) to verify whether amygdala seed-based results converge with those identified via rGBC (which may occur in places outside of functionally restricted patterns). Therefore, future studies should additionally constrain analyses to the medial PFC showing significant connectivity with the amygdala in healthy subjects (to add further power).

Lastly, given present focal findings, one direction that may further elucidate the pathophysiology of bipolar illness, is to relate observed dysconnectivity patterns that are predictive of symptoms with spatial patterns of gene expression known to affect cortical development(61). Recent advances in transcriptomics offer a quantitative approach toward characterizing the transcriptional landscape of PFC. Relating these spatial gene expression maps to fMRI offers ways to constrain our search for genes that exhibit expression in areas showing functional abnormalities with our neuroimaging markers. We acknowledge that bipolar illness is not exclusively genetic, but rather that indexes of dysconnectivity derived using novel measures could be employed to track spatio-temporal expression of genes that confer risk for development of bipolar illness.

Prefrontal Dysconnectivity and Psychosis

We examined the association between psychotic symptoms and prefrontal dysconnectivity in three ways: i) comparison of psychotic bipolar patients with controls; ii) comparison of patients with and without a history of psychosis; and iii) examination of lifetime history of psychosis severity and prefrontal dysconnectivity. All three comparisons indicated that psychotic bipolar patients exhibit a more severe pattern of mPFC rGBC and amygdala-mPFC/DLPFC coupling, further highlighted by individual-difference analyses. Interestingly, there was a mirror-like pattern between mPFC rGBC and amygdala-mPFC coupling, possibly reflecting reduced within-PFC integration, but higher connectivity due to compensatory regulation over the amygdala (previously reported for mPFC-insula coupling(54)). Importantly, given that patients were asymptomatic at the time of assessment, our findings support the notion that observed dysconnectivity constitutes a trait-like feature and may be related to illness risk and relapse vulnerability rather than current psychotic symptom expression. Thus, mPFC dysconnectivity may be a marker for disease risk, a possibility worth examining in at-risk or prodromal populations.

These results also extend prior findings of reduced prefrontal connectivity in schizophrenia, which were centered on right DLPFC and left inferior frontal junction(36). Although present rGBC analysis in bipolar illness only identified mPFC dysconnectivity, we found reduced amygdala-DLPFC connectivity in bipolar disorder that was particularly associated with psychosis. In contrast, higher amygdala-mPFC connectivity was present even in patients without psychosis history. One possibility is that while mPFC dysconnectivity may constitute a risk factor for bipolar disorder more generally, lateral prefrontal dysfunction may be particularly associated with risk for psychotic symptoms. Thus, present results suggest a two-part hypothesis whereby different aspects of frontal dysconnectivity may be responsible for psychosis vs. mood instability(62, 63). One possibility is that psychosis and
mood instability may arise due to separate processes that overlap in their anatomy and may be inherited together through distinct vulnerabilities combining via mechanisms such as assortative mating to yield psychotic bipolar illness. An alternative possibility is that these apparently separate clinical illnesses represent different phenomenological expressions of the same underlying problem at a neural circuit level, consistent with the proposal suggested by the Research Domain Criteria (RDoC) initiative(26).

Future studies should further delineate common and unique aspects of neuropathology underlying these co-morbid but distinct symptom presentations. Current findings illustrate the need for a direct comparison of clinical groups presenting with psychotic symptoms, but possibly uniquely different aspects of cortical neuropathology. A complicating factor between investigations is psychotic illness duration/severity and its effect on prefrontal cortical circuits. It is possible that illness duration differentially impacts patterns of cortical connectivity. Similarly, acute psychotic states may be marked by a distinct pattern of prefrontal connectivity disruptions than those found in chronic patients(64). Thus, future work should quantify differences in prefrontal rGBC/fcMRI in psychotic illness that may relate to time, severity, and co-morbidity. Such an approach, capitalizing on GBC’s data-driven advantages and ability to deal with individual differences in connectivity patterns(36), may provide a tool for linking patterns of prefrontal dysconnectivity with psychotic illness heterogeneity.

**Limitations**

Present findings should be interpreted within the confines of several limitations. First, we allowed for co-morbid anxiety and history of drug/alcohol abuse/dependence to obtain a more ecologically-valid sample (although effects remain unchanged when we co-varied for these variables). Future studies should delineate to what extent present results replicate when examining subgroups with and without such co-morbid diagnoses. Second, patients were remitted (2 weeks) and we examined findings as a function of psychotic history. An important future direction is to examine the extent to which these patterns hold as severity of psychosis increases during mood episodes and to fully role out the possibility that differences in symptoms may reflect general psychopathology rather than psychosis history per se. Third, due to correlational nature of the analyses, it is unclear whether changes in connectivity reflect the cause of the mood disturbance versus the consequence of the illness. Thus, it will be critical to examine if connectivity patterns relate to illness duration, number of episodes and/or frequency of cycling, and manifest in at-risk populations. Fourth, despite convergence, the rGBC/seed-based findings are exploratory, given the voxel-wise search for prefrontal dysconnectivity and should also be verified using an independent replication. Similarly, it will be important to verify amygdala findings using identified mPFC and DLPFC as seeds via an independent sample (to ensure region selection independence(53)). This also applies to the individual difference analyses, which are not completely orthogonal to the originally presented results (thought they add convergent effects). Fifth, there is likely to be further functional specialization within the amygdala itself that we currently cannot capture in our study(65), which should be examined prospectively. Lastly, although when used as covariates medications did not alter the reported effects, reported patterns should be replicated in unmedicated samples(66).

**Conclusion**

Current findings substantially extend prior work in bipolar illness using a recently developed tool designed to detect global disruptions in prefrontal connectivity, applied to a well-powered sample with carefully matched across-group demographics and SNR. We found reduced mPFC connectivity with the rest of PFC in bipolar disorder – a pattern that was inversely correlated with psychosis history. Critically, an independent amygdala seed-based
analysis revealed elevated connectivity with a highly proximal mPFC region. These convergent yet independent effects highlight that mPFC dysconnectivity may represent a potential trait characteristic or risk factor of the disorder. Furthermore, given that the observed pattern of prefrontal dysconnectivity varied as a function of psychosis history (similar to findings in schizophrenia) suggests that disrupted PFC connectivity may be important for development of psychosis trans-diagnostically. Overall, our convergent findings suggest that disruption of prefrontal/limbic networks, particularly mPFC, may be a possible biomarker for bipolar disease risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support for this study was provided by RO1 MH080912 (PI: DC Glahn). We would like to thank Dr. Pasko Rakic and Dr. Nenad Sestan for insightful comments and suggestions regarding current findings. We would also like to thank two anonymous Reviewers and Dr. Angus W. MacDonald III for their excellent feedback and constructive suggestions on how to improve this manuscript.

References


34. Strasser HC, Lilyestrom J, Ashby ER, Honeycutt NA, Schretlen DJ, Pulver AE, et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with

Biol Psychiatry. Author manuscript; available in PMC 2014 March 15.


Figure 1. Global Prefrontal Dysconnectivity
(a) Significant between-group differences in prefrontal rGBC between bipolar patients and healthy participants revealed a medial prefrontal cortex region (MPFC) (x=3, y=32, z=1). The red border approximately marks the restricted PFC analysis. (b) rGBC values are shown for the mPFC region across the three groups; healthy participants (white) and bipolar patients without psychosis history (BPW, gray); bipolar patients with history of psychosis (BPP, black). Error bars represent +/- 1 standard error of the mean.
Figure 2. Amygdala Prefrontal Dysconnectivity

Significant group differences in amygdala-prefrontal fcMRI between bipolar disorder subgroups and healthy controls. (a) Yellow/red foci mark regions where bipolar patients with a history of psychosis showed increased amygdala connectivity relative to non-psychotic patients and healthy controls. This pattern was centered on the medial prefrontal cortex (mPFC) (x=1, y=41, z=-3). The red border approximately marks the restricted PFC analysis. (b) A right DLPFC region (x=34, y=43, z=30) is shown in blue for which bipolar patients with a history of psychosis showed decreased amygdala connectivity relative to non-psychotic patients and healthy controls. The rGBC values are shown across both foci for controls (white), bipolar patients without a history of psychosis (BPW, grey) and bipolar patients with history of psychosis (BPP, black). Error bars represent +/- 1 standard error of the mean.
Figure 3. rGBC, Amygdala-Prefrontal Dysconnectivity and Lifetime Psychotic Symptom Severity

(a) Trend-level inverse relationship between mPFC rGBC and lifetime positive psychotic symptom severity across the entire sample of bipolar patients (rho = −.22, p = .07).

(b) Significant positive relationship between amygdala-mPFC fcMRI and lifetime positive psychotic symptom severity across the entire sample of bipolar patients (rho = .31, p < .015).

(c) Significant inverse relationship between amygdala-DLPFC fcMRI and lifetime positive psychotic symptom severity across the entire sample of bipolar patients (rho = −.44, p < .0001). Direction of all reported individual difference effects show strong convergence with main effects. The scale on the x-axis captures a clinician-rated severity index that ranges from 0 (absent) to 4 (Very severe; Gross or nearly constant effect on function) (67).
Table 1

Demographics

<table>
<thead>
<tr>
<th></th>
<th>Bipolar I, Psychosis Hx</th>
<th>Bipolar I, No Psychosis Hx</th>
<th>Healthy Comparison</th>
<th>Significance (HC, BPP, BPW)</th>
<th>Significance (BPW vs. BPP)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M (SD)</td>
<td>M (SD)</td>
<td>M (SD)</td>
<td>F val / Chi-Sq</td>
<td>p val, 2-tail</td>
</tr>
<tr>
<td>Sample Size</td>
<td>34 (SD)</td>
<td>34 (SD)</td>
<td>51</td>
<td>2.96</td>
<td>0.23</td>
</tr>
<tr>
<td># Female (%)</td>
<td>21 (62%)</td>
<td>26 (76%)</td>
<td>30 (59%) 31.14</td>
<td>1.24</td>
<td>0.29</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>34.0 (10.8)</td>
<td>29.85 (11.9)</td>
<td>10.6</td>
<td>3.80</td>
<td>0.025*</td>
</tr>
<tr>
<td>Education</td>
<td>13.94 (1.6)</td>
<td>14.38 (2.0)</td>
<td>15.1 (2.1)</td>
<td>2.02</td>
<td>0.14</td>
</tr>
<tr>
<td>Mother’s Education</td>
<td>13.62 (2.9)</td>
<td>14.45 (2.3)</td>
<td>13.25 (2.7)</td>
<td>1.49</td>
<td>0.19</td>
</tr>
<tr>
<td>Father’s Education</td>
<td>14.62 (3.4)</td>
<td>15.27 (3.8)</td>
<td>12.6 (4.0)</td>
<td>4.65</td>
<td>0.02*</td>
</tr>
<tr>
<td>Mean Parental Education</td>
<td>14.12 (2.8)</td>
<td>14.86 (2.7)</td>
<td>12.94 (3.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical Course

|                      |                      |                      |                      |                          |                          |                           |
| Age at Diagnosis     | 18.06 (6.0)          | 17.88 (6.2)          | N/A                 | -                         | -                         | 0.12                      | 0.91                      |
| Duration of Illness  | 14.5 (10.1)          | 13.38 (10.9)         | N/A                 | -                         | -                         | 0.40                      | 0.69                      |

Current Symptomatology

| Depression (HAMD)    | 3.29 (3.2)           | 4 (4.1)              | 0.27 (0.7)           | 21.03                      | 0.0001*                   | 0.78                      | 0.43                      |
| Mania (YMRS)         | 2.44 (3.2)           | 2.85 (3.8)           | 0.2 (0.5)            | 12.8                       | 0.0001*                   | 0.48                      | 0.63                      |
| Psychosis (BPRS)     | 28.85 (4.4)          | 27.71 (3.7)          | 24.5 (0.9)           | 22.9                       | 0.0001*                   | 1.17                      | 0.25                      |

Medications, n (%)

| Mood stabilizer(s)   | 19 (56%)             | 17 (50%)             | N/A                 | -                         | -                         | 0.23                      | 0.62                      |
| Antidepressant(s)    | 12 (35%)             | 17 (50%)             | N/A                 | -                         | -                         | 1.5                       | 0.22                      |
| Atypical Antipsychotic(s) | 15 (44%)      | 8 (24%)              | N/A                 | -                         | -                         | 3.2                       | 0.07                      |
| Anxiolytic/Benzodiazepines(s) | 12 (35%)       | 12 (35%)             | N/A                 | -                         | -                         | 0                         | 1                         |
| Lithium              | 7 (21%)              | 4 (12%)              | N/A                 | -                         | -                         | 0.98                      | 0.32                      |
| Unmedicated          | 6 (18%)              | 5 (15%)              | N/A                 | -                         | -                         | 0.1                       | 0.74                      |
| Typical Antipsychotic(s) | 0 (0%)            | 1 (3%)               | N/A                 | -                         | -                         | 1.01                      | 0.31                      |

Cocorbid Diagnoses, n (%)

<p>| Anxiety              | 15 (44%)             | 16 (47%)             | N/A                 | -                         | -                         | 0.06                      | 0.81                      |</p>
<table>
<thead>
<tr>
<th></th>
<th>Bipolar I, Psychosis Hx</th>
<th>Bipolar I, No Psychosis Hx</th>
<th>Healthy Comparison</th>
<th>Significance (HC, BPP, BPW)</th>
<th>Significance (BPW vs. BPP)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M (SD)</td>
<td>M (SD)</td>
<td>M (SD)</td>
<td>F val / Chi-Sq</td>
<td>p val, 2-tail</td>
</tr>
<tr>
<td>Alcohol</td>
<td>18 (53%)</td>
<td>21 (62%)</td>
<td>N/A</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Drug use history</td>
<td>15 (44%)</td>
<td>14 (41%)</td>
<td>N/A</td>
<td>-</td>
<td>0.06</td>
</tr>
</tbody>
</table>

BPP, Bipolar patients with psychosis history; BPW, Bipolar patients without psychosis history; BPRS, Brief Psychiatric Rating Scale; HAMD, Hamilton Depression rating scale; Hx, history; YMRS, Young Mania Rating Scale; M, Mean; SD, Standard Deviation; age, education levels, parental education, age at diagnosis and duration of illness are expressed in years.

* denotes a significant F statistic for the 1-way between-group ANOVA. Of note, no pair-wise BPP-BPW comparisons reached significance.
### Table 2

**Region Coordinates**

<table>
<thead>
<tr>
<th>X</th>
<th>Y</th>
<th>Z</th>
<th>Hemisphere</th>
<th>Anatomical Landmark</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PFC rGBC Group Differences</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>1</td>
<td>Midline</td>
<td>Medial prefrontal cortex / anterior cingulate gyrus</td>
</tr>
<tr>
<td><strong>PFC-amygdala fcMRI Group Differences</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>41</td>
<td>-3</td>
<td>Midline</td>
<td>Medial prefrontal cortex / anterior cingulate gyrus</td>
</tr>
<tr>
<td>34</td>
<td>43</td>
<td>30</td>
<td>Right</td>
<td>Middle frontal gyrus / dorso-lateral PFC</td>
</tr>
</tbody>
</table>